-$0.39 EPS Expected for Tandem Diabetes Care Inc (TNDM) This Quarter
Equities analysts predict that Tandem Diabetes Care Inc (NASDAQ:TNDM) will post earnings per share of ($0.39) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Tandem Diabetes Care’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.44). Tandem Diabetes Care reported earnings of ($3.09) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 87.4%. The firm is scheduled to issue its next earnings results on Thursday, October 25th.
On average, analysts expect that Tandem Diabetes Care will report full year earnings of ($3.17) per share for the current financial year, with EPS estimates ranging from ($3.59) to ($2.81). For the next fiscal year, analysts forecast that the company will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.25) to ($0.54). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Monday, July 30th. The medical device company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.82). The firm had revenue of $34.10 million during the quarter, compared to the consensus estimate of $29.68 million. The firm’s revenue for the quarter was up 60.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.44) earnings per share.
Shares of Tandem Diabetes Care stock traded down $0.24 on Wednesday, reaching $38.37. 4,577,361 shares of the company were exchanged, compared to its average volume of 3,054,667. The firm has a market capitalization of $2.02 billion, a PE ratio of -2.98 and a beta of 0.02. The company has a quick ratio of 2.43, a current ratio of 3.02 and a debt-to-equity ratio of 2.97. Tandem Diabetes Care has a fifty-two week low of $2.14 and a fifty-two week high of $40.04.
In other Tandem Diabetes Care news, Director Richard P. Valencia purchased 1,754 shares of the company’s stock in a transaction that occurred on Friday, August 3rd. The shares were purchased at an average cost of $28.50 per share, with a total value of $49,989.00. Following the completion of the transaction, the director now owns 1,754 shares of the company’s stock, valued at $49,989. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.30% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of TNDM. Wasatch Advisors Inc. grew its stake in Tandem Diabetes Care by 225.2% in the first quarter. Wasatch Advisors Inc. now owns 905,977 shares of the medical device company’s stock valued at $4,494,000 after purchasing an additional 627,410 shares in the last quarter. Frontier Capital Management Co. LLC boosted its stake in shares of Tandem Diabetes Care by 475.8% during the 1st quarter. Frontier Capital Management Co. LLC now owns 2,720,937 shares of the medical device company’s stock worth $13,496,000 after acquiring an additional 2,248,382 shares in the last quarter. First Mercantile Trust Co. boosted its stake in shares of Tandem Diabetes Care by 1,051.3% during the 1st quarter. First Mercantile Trust Co. now owns 44,866 shares of the medical device company’s stock worth $223,000 after acquiring an additional 40,969 shares in the last quarter. Northern Trust Corp bought a new stake in shares of Tandem Diabetes Care during the 1st quarter worth about $415,000. Finally, Cetera Advisor Networks LLC bought a new stake in shares of Tandem Diabetes Care during the 1st quarter worth about $117,000. Hedge funds and other institutional investors own 59.48% of the company’s stock.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Further Reading: Stock Symbols Definition, Examples, Lookup
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.